What is the approach to evaluating and managing a patient with thrombocytopenia?

Workup of Thrombocytopenia

Initial Assessment and Confirmation

Begin by confirming true thrombocytopenia through repeat testing in a heparin or sodium citrate tube to exclude pseudothrombocytopenia from EDTA-dependent platelet agglutination 1, 2.

Essential History Elements

• Medication exposure: All prescription and non-prescription drugs, alcohol, quinine (tonic water), environmental toxins 1
• Infection risk factors: HIV, hepatitis C, recent viral illness, parvovirus, CMV 1
• Autoimmune conditions: Systemic lupus erythematosus, antiphospholipid syndrome, thyroid disease 1
• Hematologic disorders: Prior malignancy, lymphoproliferative disorders, bone marrow disease 1
• Recent events: Transfusions (posttransfusion purpura), vaccinations, heparin exposure 1, 3
• Family history: Inherited thrombocytopenias (Wiskott-Aldrich, Bernard-Soulier, MYH9-related disease) 1
• Liver disease: Alcoholic cirrhosis, chronic hepatitis 1

Physical Examination Findings

Physical examination should be normal except for bleeding manifestations in isolated thrombocytopenia 1. Key findings that suggest alternative diagnoses include:

• Moderate to massive splenomegaly: Suggests portal hypertension, lymphoproliferative disease, or storage disorders (mild splenomegaly may occur in younger ITP patients) 1
• Hepatomegaly or lymphadenopathy: Indicates HIV, SLE, or lymphoproliferative disease 1
• Constitutional symptoms: Fever or weight loss suggests systemic disease 1

Laboratory Workup Algorithm

Tier 1: Essential Initial Tests (All Patients)

• Complete blood count with differential and reticulocyte count: Confirms isolated thrombocytopenia versus pancytopenia 1, 4
• Peripheral blood smear: Identifies schistocytes (TTP/HUS), leukocyte inclusions (MYH9), giant/small platelets (inherited thrombocytopenia), or platelet clumping 1
• HIV and hepatitis C serology: Recommended for all adults regardless of risk factors or geographic location 1, 4

Tier 2: Tests of Established Utility (Based on Clinical Context)

• Bone marrow examination: Indicated for patients >60 years, systemic symptoms, abnormal signs, or consideration of splenectomy; include aspirate, biopsy, flow cytometry, and cytogenetics 1
• Helicobacter pylori testing: Urea breath test or stool antigen preferred over serology in adults with typical ITP 1
• Blood group Rh(D) typing: If anti-D immunoglobulin therapy considered 1
• Direct antiglobulin test: Evaluates for autoimmune hemolysis 1
• Pregnancy test: Women of childbearing potential 1

Tier 3: Tests of Potential Utility (Selected Patients)

• Antiphospholipid antibodies (lupus anticoagulant, anticardiolipin): Found in 40% of ITP patients; test if antiphospholipid syndrome symptoms present 1, 4
• Antinuclear antibodies: May predict chronicity in childhood ITP 1
• Antithyroid antibodies and TSH: 8-14% of ITP patients develop clinical thyroid disease 1
• Quantitative immunoglobulins (IgG, IgA, IgM): Recommended in children with persistent/chronic ITP 1, 4
• Viral PCR for parvovirus and CMV: If chronic infection suspected 1

Tests NOT Recommended

• Platelet-associated IgG (PaIgG): Elevated in both immune and non-immune thrombocytopenia 1
• Bleeding time: No proven diagnostic utility 1
• Thrombopoietin levels: Does not guide management 1
• Platelet survival studies: Unproven benefit 1

Risk Stratification by Platelet Count

Treatment decisions must be based on bleeding symptoms and clinical context, not platelet count alone 5, 4.

Platelet Count ≥50,000/μL

• No immediate intervention required in absence of bleeding symptoms 4
• Full therapeutic anticoagulation safe without platelet transfusion support 5, 4
• No activity restrictions necessary 5

Platelet Count 25,000-50,000/μL

• Increased bleeding risk but prophylactic transfusion NOT routinely indicated unless active bleeding 4
• Reduce anticoagulation to 50% therapeutic LMWH dose or prophylactic dosing if thrombosis present 5, 4
• Avoid direct oral anticoagulants (DOACs) due to lack of safety data 5, 4

Platelet Count <25,000/μL

• Temporarily discontinue anticoagulation; resume when count >50,000/μL without transfusion support 5
• Consider hospitalization if count <20,000/μL or bleeding intensifies 5

Platelet Count <10,000/μL

• High risk of serious bleeding; prophylactic platelet transfusion recommended 2, 4

Common Pitfalls to Avoid

• Do not assume ITP without excluding secondary causes, particularly medications and infections 5
• Do not initiate corticosteroids based solely on platelet count in asymptomatic patients with counts ≥30,000/μL 5, 4
• Do not attempt to normalize platelet counts as treatment goal; target ≥50,000/μL to reduce bleeding risk 5, 4
• Do not use DOACs with platelets <50,000/μL 5, 4
• Do not give prophylactic platelet transfusions in ITP or TTP 4

Urgent Referral Criteria

Immediate emergency department referral if 5:

• Patient acutely unwell
• Active significant bleeding present
• Rapid decline in platelet count observed

Urgent hematology referral if 5:

• Cause unclear after initial workup
• Platelet count continues declining despite management
• Platelet count drops below 50,000/μL